VELO Respiratory Test
Influenza A, Influenza B, COVID-19
ApprovedActive
Key Facts
About LEX Diagnostics
LEX Diagnostics is a private, Cambridge-UK company founded in 2020 as a spin-out from TTP Group, focusing on revolutionizing point-of-care diagnostics with its ultra-fast PCR technology. The company achieved a major milestone in February 2026 with FDA 510(k) clearance and CLIA waiver for its LEX VELO Respiratory Test for Flu A, Flu B, and COVID-19. With a compact, user-friendly system designed for waived settings, LEX is positioned to address the critical need for rapid, accurate molecular testing outside central labs. The company is backed by TTP Group and a significant third-party investor, building a team to commercialize its platform and expand its test menu.
View full company profile